VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update
Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video
Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC
Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
Volition Appoints Dr. Phillip Barnes to Board of Directors
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
